As a follow on to the potential of 27mer DsiRNAs as a key platform for drug discovery and development, we are happy to report:
15.07.2008 13:34
Dicerna Pharmaceuticals, a Second Generation RNA Interference Company, Completes Second Closing of Series A Financing; Unveils Strategic Focus
Dicerna Pharmaceuticals, Inc. (www.dicerna.com), an RNA interference company developing novel therapeutics utilizing proprietary [...]
-
Back-story Related Links
-
Blogroll
-
Featured Orgs
-
Neuromics
-
Pubs and Data
-
The Book Nook
-
Subscribe
You can subscribe to our RSS feed or by e-mail below.
-
Connect





